Bernstein Harold sold $381K of MAZE
Bernstein Harold (President, R&D & CMO) sold 14,853 shares of Maze Therapeutics, Inc. (MAZE) at an average of $25.66 ($25.57–$26.36, $0.38M total) across 2 trades on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The complete exit of a senior R&D executive may prompt short‑term selling pressure, though the pre‑arranged 10b5‑1 plan tempers speculation about motive.
Market read
Primary disclosure of a senior insider's full exit; modest relevance for traders monitoring Maze Therapeutics.
What to watch
Potential upcoming clinical data releases or financing events that may offset the sell signal.
Background
SEC Form 4 filing discloses insider transactions; such filings are primary sources of new corporate information.
Ticker impact
President of R&D & CMO sold 14,853 shares for $381,112 via a 10b5‑1 plan, leaving zero holdings.
likely pressure as the market prices in the insider sell
A senior executive fully exited his position, which traders often interpret as a bearish signal.
Market effects
Minimal impact on the broader biotech sector; the sale is company‑specific.
No discernible effect on regional markets.
Limited to investors tracking Maze Therapeutics.
Counterpoint
The sale could be purely liquidity‑driven under a pre‑arranged plan, not a confidence issue.
Key entities
- companyMaze Therapeutics, Inc.
Biotech firm developing therapies for rare diseases.
- personBernstein Harold
President, R&D & CMO of Maze Therapeutics.
